Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04012476
Other study ID # ICG-Parathyroid
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date November 2016
Est. completion date October 2020

Study information

Verified date July 2019
Source Hospital Son Espases
Contact Jaime Bonnín Pascual, MD
Phone 871205959
Email jaime.bonnin@ssib.es
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The intensity of parathyroid fluorescence that occurs after intravenous injection of indocyanine green during the performance of a total thyroidectomy correlates with postoperative parathyroid function and could be used as a diagnostic marker of postoperative hypoparathyroidism and hypocalcemia.


Description:

The main objective of the study is to compare the intensity of parathyroid fluorescence among patients who present post-thyroidectomy hypocalcemia with that of patients who do not have it. Therefore, the following points will be studied:

- To study the correlation between parathyroid vascularization (intraoperative fluorescence intensity) and postoperative glandular function (serum calcium and parathormone levels).

- To compare the surgeon's subjective assessment of parathyroid fluorescence in the groups of patients with and without postoperative hypocalcemia.

- To compare the objective assessment of parathyroid fluorescence, by using specific computer software developed ad hoc, in the groups of patients with and without postoperative hypocalcemia.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date October 2020
Est. primary completion date March 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients who are going to undergo total thyroidectomy, with or without cervical lymph node dissection.

- Visualization of 2 or more parathyroid glands during the surgical act.

- Normal renal and hepatic functions.

- Absence of a history of hypersensitivity reactions to iodine or indocyanine green.

- Able to understand the nature and protocol of the study and its procedures

- Willingness to participate with the subsequent signing of informed consent.

Exclusion Criteria:

- Age <18 years

- Hepatic or renal insufficiency

- Hypersensitivity to iodine or to indocyanine green.

- Pregnancy or lactation

- Inability to understand the nature and procedures of the study.

- Patients with known preoperative hyperparathyroidism.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Indocyanine Green
Administration of 5 mg of intravenous indocyanine green after total thyroidectomy for measurement of parathyroid fluorescence under infrared light

Locations

Country Name City State
Spain Hospital Universitari Son Espases Palma De Mallorca Illes Balears

Sponsors (2)

Lead Sponsor Collaborator
Hospital Son Espases Universitat de les Illes Balears

Country where clinical trial is conducted

Spain, 

References & Publications (7)

Bonnin-Pascual J, Álvarez-Segurado C, Jiménez-Segovia M, Bianchi A, Bonnin-Pascual F, Molina-Romero FX, González-Argente FX. Contributions of fluorescence to endocrine surgery. Cir Esp. 2018 Nov;96(9):529-536. doi: 10.1016/j.ciresp.2018.09.005. Epub 2018 — View Citation

Gálvez-Pastor S, Torregrosa NM, Ríos A, Febrero B, González-Costea R, García-López MA, Balsalobre MD, Pastor-Pérez P, Moreno P, Vázquez-Rojas JL, Rodríguez JM. Prediction of hypocalcemia after total thyroidectomy using indocyanine green angiography of parathyroid glands: A simple quantitative scoring system. Am J Surg. 2019 Jan 4. pii: S0002-9610(18)31264-9. doi: 10.1016/j.amjsurg.2018.12.074. [Epub ahead of print] — View Citation

Lang BH, Wong CK, Hung HT, Wong KP, Mak KL, Au KB. Indocyanine green fluorescence angiography for quantitative evaluation of in situ parathyroid gland perfusion and function after total thyroidectomy. Surgery. 2017 Jan;161(1):87-95. doi: 10.1016/j.surg.2016.03.037. Epub 2016 Nov 10. — View Citation

Rudin AV, McKenzie TJ, Thompson GB, Farley DR, Lyden ML. Evaluation of Parathyroid Glands with Indocyanine Green Fluorescence Angiography After Thyroidectomy. World J Surg. 2019 Jun;43(6):1538-1543. doi: 10.1007/s00268-019-04909-z. — View Citation

Vidal Fortuny J, Belfontali V, Sadowski SM, Karenovics W, Guigard S, Triponez F. Parathyroid gland angiography with indocyanine green fluorescence to predict parathyroid function after thyroid surgery. Br J Surg. 2016 Apr;103(5):537-43. doi: 10.1002/bjs.10101. Epub 2016 Feb 11. — View Citation

Vidal Fortuny J, Sadowski SM, Belfontali V, Guigard S, Poncet A, Ris F, Karenovics W, Triponez F. Randomized clinical trial of intraoperative parathyroid gland angiography with indocyanine green fluorescence predicting parathyroid function after thyroid surgery. Br J Surg. 2018 Mar;105(4):350-357. doi: 10.1002/bjs.10783. Epub 2018 Feb 6. — View Citation

Zaidi N, Bucak E, Yazici P, Soundararajan S, Okoh A, Yigitbas H, Dural C, Berber E. The feasibility of indocyanine green fluorescence imaging for identifying and assessing the perfusion of parathyroid glands during total thyroidectomy. J Surg Oncol. 2016 Jun;113(7):775-8. doi: 10.1002/jso.24237. Epub 2016 Apr 4. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Calcemia Serum calcium level at 24 hours postoperatively Day 1 after surgery
Primary Subjective parathyroid fluorescence Fluorescence intensity of the parathyroid glands after administration of indocyanine green (ICG), measured on a subjective analogue scale (0: no fluorescence, 1: hypofluorescence or heterogeneous fluorescence, 2: homogeneous hyperfluorescence). Intraoperatively
Primary Objective parathyroid fluorescence Fluorescence intensity of the parathyroid glands after administration of indocyanine green (ICG), measured by specific computer software developed ad hoc. Intraoperatively
Secondary Age Patient's age Baseline
Secondary Sex Patient's gender Baseline
Secondary Body mass index Patient's BMI Baseline
Secondary Surgery date Day when surgery takes place Baseline
Secondary Preoperative diagnosis Thyroid pathology indicating total thyroidectomy (thyroid carcinoma, atypical of uncertain significance, goiter or lymphocytic thyroiditis) Baseline
Secondary Vitamin D Preoperative vitamin D level Preoperative blood test
Secondary PTH preop Preoperative PTH level Immediately before surgery
Secondary PTH 10 min PTH levels 10 minutes post-thyroidectomy 10 minutes post-thyroidectomy
Secondary Surgery Scope of surgery: total thyroidectomy (TT), TT with central neck dissection, or TT with functional lateral neck dissection Inmediately after surgery
Secondary Time Duration of surgery Inmediately after surgery
Secondary Parathyroid glands Number of parathyroid glands located during surgery, During surgery
Secondary Parathyroid gland location Location of the parathyroid glands (superior right, inf-right, sup-left, inf-left). During surgery
Secondary Pathologic result Outcome of thyroid pathology (papillary carcinoma, nodular hyperplasia or lymphocytic thyroiditis) during the first month after surgery
Secondary Thyroid weight Thyroid weight during the first month after surgery
Secondary PG in piece Presence of parathyroid glands in the surgical piece and number during the first month after surgery
Secondary Stay Number of days of postoperative hospital stay until the day of hospital discharge, measured as full days of 24 hours During the first month after surgery
Secondary Drain Presence and number of surgical drainages Inmediately after surgery
Secondary PTH day 1 PTH levels in the postoperative follow-up, Day 1 after surgery
Secondary Complications Emergence of postoperative complications. During the first month after surgery
See also
  Status Clinical Trial Phase
Completed NCT02892253 - Parathyroid Autofluorescence Visualization in Thyroid Surgery: Impact on Postoperative Hypocalcemia N/A
Completed NCT05043584 - Near-infrared Autofluorescence (NIRAF)-Guided Total Thyroidectomy: Impact in Low-volume, Non-parathyroid Institutions N/A
Recruiting NCT05885256 - Clinical Assessment of Low Calcium In traUMa (CALCIUM)
Recruiting NCT04160637 - Is There Benefit From Early Postoperative PTH Monitoring?
Completed NCT00506103 - The No-Tie Technique Using the Harmonic Scalpel in Total Thyroidectomy With Central Neck Dissection: A Prospective Randomized Study N/A
Recruiting NCT05585593 - Registry for Hypoparathyroidism Wuerzburg
Recruiting NCT05586529 - Effect of Preoperative High-dose Cholecalciferol in Prevention of Post-thyroidectomy Hypocalcaemia N/A
Completed NCT01868750 - Phase II Pre-operative Vitamin D Supplementation to Prevent Post-thyroidectomy Hypocalcemia Phase 2
Completed NCT00668200 - Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast® Phase 4
Terminated NCT00623974 - Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia Phase 2
Completed NCT00630214 - Prevention of Hypocalcemia in Patients Undergoing Total Thyroidectomy Plus Central Neck Dissection Phase 2
Not yet recruiting NCT03685877 - Hypocalcemia in Infants and Children
Terminated NCT00001151 - Studies With 1,25-Dihydroxycholecalciferol Phase 2
Completed NCT04750460 - Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa). Phase 3
Not yet recruiting NCT03063060 - The Impact of Vitamin D Deficiency on Hypocalcaemia Following Total Thyroidectomy N/A
Not yet recruiting NCT04304573 - Is Correcting Total Serum Calcium Levels Important After Thyroidectomy
Recruiting NCT05216419 - Prevention of Postoperative Hypocalcemia of Oral Vitamin D Supplementation Before Total Thyroidectomy Phase 4
Recruiting NCT04775381 - Total Post-thyroidectomy Hypocalcemia After Preoperative Cholecalciferol Supplementation Phase 3
Active, not recruiting NCT01632514 - Vitamin D Deficiency and Postoperative Hypocalcemia Phase 4
Recruiting NCT05260255 - Effect of Vitamin D Supplement on Disease Activity in SLE N/A